FindTrial
Sign In

A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety.

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520336-14-00
Acronym
FOVOCIP
Enrollment
156
Registered
2025-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autologous or allogeneic hematopoietic stem cell transplantation (HSCT)., Post-chemotherapy neutropenia with high risk of developing infection in patients with acute leukemia undergoing induction

Brief summary

febrile neutropenia requiring antibacterial treatment, Absolute Neutrophil Count (ANR) >0.5x109/L, If the subject fails to achieve more than 0.5x109/L neutrophils the study will end when more than 60 days have elapsed since the onset of neutropenia, or on the first day of the next chemotherapy cycle (whichever is earlier), death

Interventions

DRUGFOSFOMYCIN
DRUGCIPROFLOXACIN

Sponsors

Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De Asturias
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
febrile neutropenia requiring antibacterial treatment, Absolute Neutrophil Count (ANR) >0.5x109/L, If the subject fails to achieve more than 0.5x109/L neutrophils the study will end when more than 60 days have elapsed since the onset of neutropenia, or on the first day of the next chemotherapy cycle (whichever is earlier), death—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026